95 related articles for article (PubMed ID: 11840140)
1. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants.
Sirvent-Von Bueltzingsloewen A; Morand P; Buisson M; Souillet G; Chambost H; Bosson JL; Bordigoni P
Bone Marrow Transplant; 2002 Jan; 29(1):21-8. PubMed ID: 11840140
[TBL] [Abstract][Full Text] [Related]
2. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
4. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
5. [EBV quantification in children after allogeneic hematopoietic stem cell transplantation].
Hubácek P; Cinek O; Kulich M; Zajac M; Keslová P; Formánková R; Starý J; Sedlácek P
Cas Lek Cesk; 2006; 145(4):301-6. PubMed ID: 16639931
[TBL] [Abstract][Full Text] [Related]
6. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
7. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
Gruhn B; Meerbach A; Häfer R; Zell R; Wutzler P; Zintl F
Bone Marrow Transplant; 2003 Jun; 31(11):1023-5. PubMed ID: 12774054
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
9. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation.
Cesaro S; Pegoraro A; Tridello G; Calore E; Pillon M; Varotto S; Abate D; Barzon L; Mengoli C; Carli M; Messina C
Transplantation; 2010 Jun; 89(12):1533-40. PubMed ID: 20463647
[TBL] [Abstract][Full Text] [Related]
10. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.
McGuirk JP; Seropian S; Howe G; Smith B; Stoddart L; Cooper DL
Bone Marrow Transplant; 1999 Dec; 24(11):1253-8. PubMed ID: 10642818
[TBL] [Abstract][Full Text] [Related]
11. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
Cesaro S; Murrone A; Mengoli C; Pillon M; Biasolo MA; Calore E; Tridello G; Varotto S; Alaggio R; Zanesco L; Palù G; Messina C
Br J Haematol; 2005 Jan; 128(2):224-33. PubMed ID: 15638858
[TBL] [Abstract][Full Text] [Related]
12. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
14. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
Okamura T; Kishimoto T; Inoue M; Honda M; Yamashita N; Wakiguchi H; Yagita M; Hosoi G; Sako M; Yasui M; Yagi K; Kawa K
Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
[TBL] [Abstract][Full Text] [Related]
15. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
[TBL] [Abstract][Full Text] [Related]
16. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
19. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation.
van Esser JW; Niesters HG; Thijsen SF; Meijer E; Osterhaus AD; Wolthers KC; Boucher CA; Gratama JW; Budel LM; van der Holt B; van Loon AM; Löwenberg B; Verdonck LF; Cornelissen JJ
Br J Haematol; 2001 Jun; 113(3):814-21. PubMed ID: 11380475
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction.
Benden C; Aurora P; Burch M; Cubitt D; Lloyd C; Whitmore P; Neligan SL; Elliott MJ
J Heart Lung Transplant; 2005 Dec; 24(12):2103-8. PubMed ID: 16364857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]